Things to note before using Cresflut

Crinecerfont, trade name Crenessity, is an innovative corticotropin-releasing factor 1 receptor antagonist, mainly used to treat typical congenital adrenal hyperplasia (CAH). As an adjunct to glucocorticoid replacement therapy, Cresflut provides patients with a new treatment option by targeting the reduction of androgen levels.

Crisflutide is suitable for adult and pediatric patients 4 years old and above with typical congenital adrenal hyperplasia (CAH) to control androgen levels. For children under 4 years old, its safety and effectiveness have not been confirmed, so its use is not recommended. In addition, patients must be diagnosed with typical CAH and undergo a comprehensive evaluation by a doctor before using Cresflutide. The dose of Cresflutide needs to be adjusted according to the patient's age and weight. The recommended dose for adults is 100 mg twice a day, taken with meals; the dose for children needs to be calculated based on body weight. If you miss a dose, take it as soon as possible, but do not double the dose.

Attention should be paid to the use of Cresflutide.Patients allergic to Cresflutide or its ingredients are prohibited from using it. If the patient has a history of drug allergies, he or she must inform the doctor in advance. and Currently there is insufficient data to prove the safety of crisflutide in pregnant and lactating women, so it should be used with caution and the pros and cons should be weighed under the guidance of a doctor if necessary. In addition, Liver and kidney insufficiency may affect drug metabolism, so the dosage needs to be adjusted or related indicators monitored under the guidance of a doctor.

Cresflutide is an adjuvant therapy for glucocorticoid replacement therapy. Patients must ensure that they have received glucocorticoid therapy and understand the need for dose adjustment before use. andBefore using Cresflutide, patients need to undergo a comprehensive physical examination, including evaluation of liver and kidney function, electrolyte levels, and adrenal gland function, to rule out potential risks. Furthermore, Patients need to inform their doctors about all medications they are taking, including prescription drugs, over-the-counter drugs, and health supplements, to avoid potential drug interactions.

After using Cresflutide, patients may experience adverse reactions such as fatigue, headache, dizziness, and joint pain, most of which are mild to moderate. If severe allergic reactions occur (such as throat tightness, rash, etc.), you need to stop taking the medicine immediately and seek medical advice.

Corticosteroids need to be continued during treatment to avoid acute adrenal insufficiency. The dose of glucocorticoids must be adjusted under the guidance of a physician and must not be lower than the dose required for replacement therapy.

In situations of increased cortisol demand, such as acute illness, severe trauma, or surgery, patients require stress doses of glucocorticoids and close monitoring of adrenal function. Patients who use Cresflutide for a long time need to regularly review androstenedione levels, liver and kidney functions, and electrolyte levels to ensure the safety of medication.

Crisflutide provides a new treatment option forCAH patients, but its use must strictly follow the indications and precautions. Patients should fully understand the potential risks before use and use the medication rationally under the guidance of a doctor. Through scientific medication and standardized management, Cresflut is expected to bring better therapeutic effects to more patients.

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218808s000,218820s000lbl.pdf